TriSalus Life Sciences IPO

TriSalus Life Sciences is a biopharma company that specializes in treatment research and development for tumors of the liver and pancreas. TriSalus involves a team of clinicians and scientists who develop systemic immunotherapies to fight tumors through its developed drug delivery methods.

Register for Details

For more details on financing and valuation of private companies similar to TriSalus Life Sciences before its SPAC, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about TriSalus Life Sciences

To invest in TriSalus Life Sciences pre-IPO

Can you invest in TriSalus Life Sciences pre-IPO?

You may invest in TriSalus Life Sciences as it is a public company listed on the NASDAQ with ticker TLSI. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of TriSalus Life Sciences before it goes public?

You can no longer sell shares of TriSalus Life Sciences on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my TriSalus Life Sciences shares?

Forge can no longer determine the value of TriSalus Life Sciences shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is TriSalus Life Sciences a publicly traded company?

TriSalus Life Sciences became a public company following its SPAC on 08/10/2023 and is now traded on the NASDAQ under the ticker TLSI.

To learn more about TriSalus Life Sciences potential IPO

Will TriSalus Life Sciences go IPO?

TriSalus Life Sciences became a public company following its SPAC on 08/10/2023 and is now traded on the NASDAQ under the ticker TLSI.

What is TriSalus Life Sciences’ IPO price?

The IPO price of TriSalus Life Sciences is not currently available.

When was TriSalus Life Sciences founded?

TriSalus Life Sciences was founded in 2009.

What is TriSalus Life Sciences funding to date?

TriSalus Life Sciences has raised $198.81MM to date.

Who are TriSalus Life Sciences’s major investors?

TriSalus Life Sciences Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
10/05/2022 Series B-2 $15.32MM $xx.xx $37.59B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
43,775,511
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
09/29/2021 Series B-3 $17.14MM $xx.xx $35.66B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
342,857,136
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
09/29/2021 Series B-1 $23.5MM $xx.xx $35.66B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
67,142,854
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
03/18/2021 Series B $85.22MM $xx.xx $16.2B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
284,065,377
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
03/02/2017 Series A-6 $16.3MM $xx.xx $8.06B Ori Healthcare Fund
Price per Share
$xx.xx
Shares Outstanding
32,601,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ori Healthcare Fund
12/02/2015 Series A-4 $2.05MM $xx.xx $5.55B High Country Venture, Kmg Capital Partners, Mcg Partners, Partisan Management Group, Tullis Health Investors
Price per Share
$xx.xx
Shares Outstanding
5,169,690
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
High Country Venture, Kmg Capital Partners, Mcg Partners, Partisan Management Group, Tullis Health Investors
12/02/2015 Series A-5 $13.08MM $xx.xx $5.55B High Country Venture, Kmg Capital Partners, Mcg Partners, Partisan Management Group, Tullis Health Investors
Price per Share
$xx.xx
Shares Outstanding
29,715,910
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
High Country Venture, Kmg Capital Partners, Mcg Partners, Partisan Management Group, Tullis Health Investors
11/07/2013 Series A-2 $9.02MM $xx.xx $4.6B Mcg Partners, Partisan Management Group & High Country Ventures
Price per Share
$xx.xx
Shares Outstanding
23,307,464
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Mcg Partners, Partisan Management Group & High Country Ventures
11/07/2013 Series A-3 $10.66MM $xx.xx $4.6B Mcg Partners, Partisan Management Group & High Country Ventures
Price per Share
$xx.xx
Shares Outstanding
24,792,020
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Mcg Partners, Partisan Management Group & High Country Ventures
07/06/2011 Series A-1 $6.53MM $xx.xx $1.86B High Country Venture, Partisan Management Group
Price per Share
$xx.xx
Shares Outstanding
5,331,943
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
High Country Venture, Partisan Management Group
Updated on: Nov 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.